title: Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis' (Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).
authors.forename: Claire
authors.initials: C
authors.lastname: Watkins
authors.forename: Yuri
authors.initials: Y
authors.lastname: Rukazenkov
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; C512478:EGFR protein, human; D066246:ErbB Receptors